Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune booster vaccine shows promise against deadly brain cancer

NCT ID NCT02649582

Disease control Sponsor: University Hospital, Antwerp Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether adding a personalized dendritic cell vaccine to standard chemotherapy can help people with newly diagnosed glioblastoma live longer. Twenty patients who had surgery and chemoradiation will receive the vaccine alongside temozolomide. The goal is to see if this combination improves overall and progression-free survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dendritic cell vaccine plus temozolomide chemotherapy
What this could lead to
If it works, this could extend survival for people with newly diagnosed glioblastoma by boosting the immune system to fight the tumor.
What could go wrong
This is an early-phase trial with only 20 participants, so results may not apply to everyone. The vaccine may not work or could cause side effects like inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

20 people

The number who actually took part.

Started

Dec 2015

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed, histologically verified glioblastoma (WHO grade IV) * Aged ≥ 18 years * Total or subtotal resection: * Total resection: macroscopic complete resection as assessed by the neurosurgeon and absence of any residual contrast-enhancing mass on post-operative (≤ 72h) brain MRI * Subtotal resection: macroscopic complete resection as assessed by the neurosurgeon, but with residual contrast-enhancement ≤ 2 cm³ on post-operative (≤ 72h) brain MRI * Signed informed consent * Willing and able to comply with the protocol as judged by the Investigator * Estimated to start with chemoradiation ≥ 28 days and ≤ 49 days following surgical resection * Fit to undergo: leukapheresis, chemoradiation, chemotherapy and immunotherapy * No corticosteroid treatment ≤ 1 week before apheresis * WHO performance status ≤ 2 * Life expectancy ≥ 3 months as estimated by the Investigator Exclusion Criteria: * History of another malignancy, except for adequately controlled basal cell skin carcinoma, squamous skin carcinoma, or carcinoma in situ of the uterine cervix or unless the investigator rationalizes otherwise * Prior radiation or chemotherapy * Any pre-existing contraindication for temozolomide treatment * Any pre-existing contraindication for contrast-enhanced brain MRI * Pregnant or breast-feeding * Documented immune deficiency or systemic immune-suppressive treatment * Known positive viral serology for HIV, HBV, HCV, or syphilis * Any other condition, either physical or psychological, or reasonable suspicion thereof on clinical or special investigation, which contraindicates the use of the vaccine, or may negatively affect patient compliance, or may place the patient at higher risk of potential treatment complications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain glioblastoma glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioblastoma multiforme of brain

Contacts and locations

Locations

  • Antwerp University Hospital

    Edegem, Antwerp, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.